As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: April 4, 2015
by Kathleen Lees for Science World Report:
Researchers from the National Taiwan Normal University Institute of Electro-optical Science and Technology along with the National Taiwan University Hospital’s Neurology Department have created the first blood test to successfully predict Alzheimer’s disease.
“Blood-based biomarkers would have the important advantage of being safe, affordable and easy to administer in large groups or in rural areas, and therefore could have an enormous impact on clinical care and clinical trials alike,” said Dr. Liana G. Apostolova, director of the neuroimaging laboratory at the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and head of the research team, via CBS Los Angeles.
“These could have an enormous impact on clinical care and clinical trials alike,” she added.
The test uses metal nanopowder, which has developed into a significant tool in medicine and serves as a platform through which scientists work to deliver drugs to diseased areas of the body in patients.
Now the test can help predict the likelihood of the disease in patients as many as eight to 10 years around from the neurodegenerative health problem. This can be particularly helpful in finding the right treatment plan for the individual. The current method of testing involves drawing spinal fluid from the patient and takes about a week to deliver results, but can be particularly invasive and may come with nerve damage and other side effects. Another method is the amyloid PET scan, which is effective but exposes the patient to radiation. It’s also known to be expensive and most insurance companies don’t cover it as a diagnostic test.
The new blood testing also carries some drawbacks, too. Finding out this kind of diagnosis early on can led to the onset of depression. But it’s chosing a treatment plan that doctors are so hopeful about for the future as the use of nanotechnology in modern medicine continues to help bring solutions to the future of disease.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.